Workflow
Gene therapy for Duchenne muscular dystrophy
icon
Search documents
Sarepta Therapeutics (NasdaqGS:SRPT) Earnings Call Presentation
2026-01-26 13:30
SRP-9001-301 PART-1 3-Year Data Topline Results Doug Ingram Chief Executive Officer Louise R. Rodino-Klapac, Ph.D. President, R&D and Technical Operations James Richardson, MA (Oxon), BMBCh, MBA, MRCP (Lon) Executive Vice President, Chief Medical Officer January 26, 2026 ©SAREPTA THERAPEUTICS, INC. 2026. ALL RIGHTS RESERVED. 1 DILLON Living with Duchenne muscular dystrophy This presentation contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be f ...